title: [Cardiologic evaluation of patients undergoing chemotherapy].
abstract: Life expectancy in patients affected by cancer has recently increased because of early diagnosis and actual therapies. In recent years, Oncology and Cardiology developed a tight relationship because of common risk factors (i.e., obesity, smoking, alcool intake, etc...), and for preventing the prothrombotic status due to cancer and the potential cardiotoxicity of chemotherapy. Cardiotoxicity incidence is reported from 1% up to 70% in retrospective analyses of drug protocols, mainly representing by left ventricular dysfunction (both reversible or irreversible), but also by arrhythmias, hypertension, atrioventricular block, coronary spasm, and arterial or venous thromboembolism. The early detection of the chemoterapy induced cardiotoxicity is now mandatory and can be obtained through a proper patients selection for different treatments and a strict monitoring during the follow-up period. The role of biomarkers of early cardiac damage, mainly, troponin I and brain natriuretic peptide-BNP, has been recently challenged, and algorithms are currently available. In the present paper, we propose how to perform a cardiological evaluation of patients undergoing chemotherapy tailored by the known adverse effects of the drugs.
authors.forename: Barbara
authors.initials: B
authors.lastname: Bordoni
authors.forename: Stefano
authors.initials: S
authors.lastname: Urbinati
authors.forename: Alicia
authors.initials: A
authors.lastname: Tosoni
authors.forename: Graziana
authors.initials: G
authors.lastname: Labanti
authors.forename: Alba
authors.initials: A
authors.lastname: Brandes
mesh_terms: D066126:Cardiotoxicity; D015897:Comorbidity; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology